ArticleFrontiers in immunology2026
Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Despite therapeutic advances, inflammatory bowel disease (IBD) remains a lifelong debilitating disorder with substantial burden. The study aimed to investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece. Methods: Between October 2023 and January 2024, adult CD and UC patients who were members of Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC) and receiving advanced therapies completed a structured self-reported questionnaire. The survey collected data on sociodemographic characteristics, smoking status, comorbidities, disease activity, disease characteristics, current medications, and patient-reported outcomes (PROs; Short Inflammatory Bowel Disease Questionnaire [SIBDQ], Work Productivity and Activity Impairment [WPAI], Patient Health Questionnaire-9 [PHQ-9], treatment satisfaction and adherence). Both univariate and multivariate logistic regression analyses were performed to determine associated factors. Results: Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease. Overall, 76.4% reported impaired QoL, 30.3% work productivity loss, and 38.4% activity impairment, while nearly half exhibited moderate-to-severe depressive symptoms. Notably, 39.1% expressed dissatisfaction with their advanced therapy, while 10.9% reported reduced adherence. No significant differences were observed between CD and UC patients across PROs, except for adherence. Higher disease activity was consistently associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction. Conclusion: Despite advanced therapies, IBD burden remains substantial among Greek patients. A considerable proportion experience poor QoL, increased work impairment, significant depressive symptoms, and persistent disease activity. Marked treatment dissatisfaction, reported by four out of ten patients, highlights an unmet need for more effective management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.